FDA approves first oral drug for treatment of spinal muscular atrophy

The U.S. Food and Drug Administration today approved Evrysdi (risdiplam) to treat patients two months of age and older with spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.
Read More

>>Hollywood's Exotic Secret For Healthy Weight Loss